Core Insights - The first domestically produced nine-valent HPV vaccine "Xinkening 9" has been officially launched in Henan province, marking a significant step in cervical cancer prevention efforts in China [1] - The introduction of this vaccine is expected to improve the low vaccination coverage in the country, primarily due to its competitive pricing compared to imported alternatives [1] Group 1: Vaccine Characteristics - The main differences between domestic and imported nine-valent HPV vaccines lie in the manufacturers, pricing, target populations, and some production details, while both have been rigorously tested for safety and efficacy [2] - The domestic vaccine is priced at 499 yuan per dose (excluding service and storage fees), totaling 521 yuan in Henan when including these additional costs [2] - The domestic vaccine utilizes a novel E. coli virus-like particle expression technology, which is claimed to induce a higher immune response compared to the recombinant protein technology used in imported vaccines [2] Group 2: Vaccination Process and Availability - The first batch of the vaccine has been distributed to various disease control centers in Henan, with expectations to cover the entire province by mid to late September [3] - Currently, the HPV vaccine is available on a self-paid basis, but there are discussions about potentially including it in the national immunization program, which would make it free for eligible individuals [4]
首款国产九价HPV疫苗河南开打 预计9月中下旬将覆盖全省
He Nan Ri Bao·2025-09-19 23:45